The data published to date suggests that the first-line immunotherapy in monotherapy strategy has become the new standard of care in locally advanced and metastatic NSCLC patients with high PD-L1 expression levels and no EGFR and ALK genomic tumor aberrations targetable mutations [9]. Here, ALK is linked to non-small cell lung carcinoma.